IDH inhibitors combined with other anticancer agents may be more effective in IDH-mutated AML than IDH inhibitors alone, but this requires better evaluation after completion of relevant ongoing and unstarted studies (e.g. NCT04774393, NCT04250051, NCT05441514). Here, IDH1 is linked to acute myeloid leukemia.